Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Glioma 6Glioblastoma 3Insulinoma 2Hypoglycemia 2Hyperinsulinism 2Congenital Hyperinsulinism 2Brain Neoplasms 2Sarcoma 1Pheochromocytoma 1Parkinsonian Disorders 1Parkinson Disease 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1Lewy Body Disease 1Infant, Newborn, Diseases 1Glucose Metabolism Disorders 1Gliosarcoma 1Glioma, Subependymal 1Ependymoma 1Endocrine System Diseases 1Carcinoma, Medullary 1Carcinoid Tumor 1Beckwith-Wiedemann Syndrome 1Astrocytoma 1

Interventions

fluorodopa F 18 1Furosemide 1Clinical Laboratory Techniques 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease × fluorodopa F 18 × 1 year × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡